Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients?
- 1 September 2000
- journal article
- clinical trial
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 178 (1) , 37-41
- https://doi.org/10.1016/s0022-510x(00)00361-0
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Evidence of interferon β-1a dose response in relapsing-remitting MSNeurology, 1999
- A Novel Bioassay for the Determination of Neutralizing Antibodies to IFNβ1bJournal of Interferon & Cytokine Research, 1998
- Correlation of the Appearance of Anti-Interferon Antibodies During Treatment and Diminution of Efficacy: Summary of an International Workshop on Anti-Interferon AntibodiesJournal of Interferon & Cytokine Research, 1998
- Incidence of exacerbations in the first 90 days of treatment with recombinant human interferon β‐1b in patients with relapsing‐remitting multiple sclerosisAnnals of Neurology, 1998
- Development of Neutralizing Antibodies in Patients with Relapsing-Remitting Multiple Sclerosis Treated with IFN-β1aJournal of Interferon & Cytokine Research, 1998
- Management of Multiple SclerosisNew England Journal of Medicine, 1997
- Systemic Recombinant Human Interferon-β Treatment of Relapsing–Remitting Multiple Sclerosis: Pilot Study Analysis and Six-Year Follow-UpJournal of Interferon Research, 1993
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983